What it is
Ipamorelin is a selective growth-hormone secretagogue receptor agonist; CJC-1295 is a growth-hormone-releasing-hormone analogue. Combined presentations are supplied as research chemicals and are not approved medicines.
The Range
CP10 · Pen · Endocrine research
Ipamorelin / CJC-1295 10 mg pen
Research-onlyEvidence: Preclinical
A research combination of a growth-hormone secretagogue and a GHRH analogue. Studied in endocrine research; not an approved therapeutic combination.
Evidence highlights
Mechanism being studied
Both act on pathways that influence pulsatile growth-hormone release in laboratory and animal studies.
Human evidence
Some early-phase pharmacokinetic studies exist for the individual compounds, but there is no adequate controlled evidence for the combination in general clinical use, and no approved indication.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.